Losartan - Global Strategic Business Report

The global market for Losartan was valued at US$1.5 Billion in 2024 and is projected to reach US$1.7 Billion by 2030, growing at a CAGR of 2.2% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Losartan market.

Global Losartan Market - Key Trends & Drivers Summarized

Why Does Losartan Remain a First-Line Treatment in Cardiovascular and Renal Therapeutics?

Losartan, an angiotensin II receptor blocker (ARB), has retained its prominence in global cardiovascular and nephrology practices due to its proven efficacy, favorable tolerability profile, and broad therapeutic scope. Originally developed to manage hypertension, its indications have expanded to include heart failure with reduced ejection fraction, diabetic nephropathy, and stroke prevention. By selectively blocking the AT1 receptor, losartan inhibits vasoconstriction and aldosterone secretion, thereby reducing blood pressure without the persistent cough or electrolyte imbalances often associated with ACE inhibitors. This pharmacodynamic advantage has positioned losartan as the preferred ARB in many treatment guidelines, particularly in patients intolerant to ACE inhibitors.

Its relevance has grown in tandem with the global rise in lifestyle-related conditions such as hypertension, type 2 diabetes, and metabolic syndrome - each of which significantly elevates the risk of cardiovascular complications. In patients with chronic kidney disease (CKD), losartan has demonstrated renal-protective effects independent of blood pressure reduction, including delaying the onset of end-stage renal disease. Additionally, its use in combination therapies - often with hydrochlorothiazide or amlodipine - has become standard practice for patients requiring multi-mechanism blood pressure control. This multifaceted therapeutic utility, coupled with wide availability as a generic, has kept losartan in high clinical demand across global healthcare systems.

How Are Formulation Improvements and Generic Penetration Shaping Market Competition?

The losartan market is characterized by intense generic competition, especially following the patent expirations of branded versions such as Cozaar and Hyzaar. This has significantly driven down costs and improved accessibility, particularly in low- and middle-income countries. Dozens of manufacturers now produce losartan in various dosages and fixed-dose combinations, creating a highly commoditized but expansive market. To differentiate within this environment, pharmaceutical companies are focusing on formulation innovation, manufacturing efficiency, and improved patient adherence solutions.

Oral formulations remain dominant, but developments in extended-release tablets and orally disintegrating tablets are expanding options for elderly or dysphagic patients. Fixed-dose combinations are also evolving, with new pairings designed to optimize compliance in patients with multiple comorbidities. Sustained-release delivery systems and once-daily regimens are being prioritized to improve adherence among chronic users. Moreover, manufacturing innovations aimed at reducing nitrosamine impurities - following regulatory scrutiny over carcinogenic contaminants in ARB supplies - have led to improved process controls and renewed regulatory trust in quality-assured losartan formulations. These trends are reinforcing product safety while supporting brand differentiation in a competitive market.

What Role Do Clinical Guidelines, Epidemiological Trends, and Access Programs Play in Market Expansion?

The inclusion of losartan in international hypertension management guidelines and essential medicines lists is a critical factor in sustaining its market footprint. Organizations such as the WHO, American Heart Association, and European Society of Cardiology continue to recommend ARBs as first-line or second-line agents for high-risk populations, including diabetics and those with chronic kidney disease. The drug’s utility in preventing cardiovascular events and slowing renal function decline in proteinuric patients gives it additional strategic value in population health management, especially in aging societies and those with high chronic disease burdens.

Epidemiological trends also support sustained demand. Hypertension affects over 1.2 billion people globally, many of whom are undiagnosed or undertreated. The global prevalence of diabetes and obesity is accelerating demand for cardioprotective agents like losartan that offer both blood pressure reduction and end-organ protection. Access initiatives by public health agencies and international NGOs are increasing availability of losartan through price negotiations, pooled procurement programs, and health insurance coverage expansion. These dynamics are particularly pronounced in Sub-Saharan Africa, Southeast Asia, and Latin America, where non-communicable diseases are rising sharply and losartan plays a pivotal role in low-cost treatment regimens.

What Is Driving Long-Term Growth and Innovation in the Losartan Market?

The growth in the losartan market is driven by several intersecting trends across therapeutic need, healthcare policy, and pharmaceutical strategy. Chief among them is the rising global burden of cardiovascular and renal disorders, especially in low-income and aging populations. As governments and health systems prioritize non-communicable disease control, losartan remains a cost-effective anchor therapy that balances clinical efficacy with economic scalability. Large-scale population screening programs for hypertension and diabetes are expanding the pool of diagnosed patients, increasing first-line losartan prescriptions.

Additionally, the movement toward integrated care models and chronic disease management is creating sustained use scenarios where losartan is prescribed for years, even decades. Pharmaceutical strategies to combine losartan with novel agents - such as SGLT2 inhibitors or endothelin receptor antagonists - are under early exploration for advanced renal and heart failure cases. Meanwhile, improved supply chain monitoring, API traceability, and AI-enabled pharmacovigilance systems are strengthening drug quality assurance in global supply chains, particularly in generic-dominated markets.

Furthermore, the drug’s favorable risk-benefit ratio continues to drive adoption in both hospital and community settings. With growing awareness of losartan’s role in protecting cardiovascular health beyond mere blood pressure control, the market outlook remains strong. This stability, combined with product life cycle optimization through improved formulations and fixed-dose innovations, is positioning losartan for sustained relevance in the global pharmaceutical landscape.

Report Scope

The report analyzes the Losartan market, presented in terms of market value (US$ Thousand). The analysis covers the key segments and geographic regions outlined below.

Segments: Dosage Form (Tablet, Powder, Suspension); Application (Hypertension Application, Stroke Application, Diabetic Nephropathy Application, Other Applications); Distribution Channel (Contract Manufacturing Distribution Channel, In-house Manufacturing Distribution Channel, Other Distribution Channels).

Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Key Insights:

• Market Growth: Understand the significant growth trajectory of the Losartan Tablet segment, which is expected to reach US$1.0 Billion by 2030 with a CAGR of a 1.9%. The Losartan Powder segment is also set to grow at 2.6% CAGR over the analysis period.
• Regional Analysis: Gain insights into the U.S. market, valued at $412.3 Million in 2024, and China, forecasted to grow at an impressive 4.3% CAGR to reach $327.3 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

• Detailed Market Analysis: Access a thorough analysis of the Global Losartan Market, covering all major geographic regions and market segments.
• Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
• Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Losartan Market.
• Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

• How is the Global Losartan Market expected to evolve by 2030?
• What are the main drivers and restraints affecting the market?
• Which market segments will grow the most over the forecast period?
• How will market shares for different regions and segments change by 2030?
• Who are the leading players in the market, and what are their prospects?

Report Features:

• Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
• In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
• Company Profiles: Coverage of players such as AdvaCare Pharma, Aurobindo Pharma, Cipla, Dr. Reddy's Laboratories, Healthy Life Pharma and more.
• Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the 48 companies featured in this Losartan market report include:

• AdvaCare Pharma
• Aurobindo Pharma
• Cipla
• Dr. Reddy's Laboratories
• Healthy Life Pharma
• Hetero Labs
• Ipca Laboratories
• Jubilant Pharmova
• Lupin Limited
• Micro Labs
• Mylan (Viatris)
• Novartis
• Pfizer
• Solco Healthcare
• Sun Pharmaceutical Industries
• Teva Pharmaceuticals
• Torrent Pharmaceuticals
• Unichem Laboratories
• Zhejiang Hisun Pharmaceutical
• Zhejiang Tianyu Pharmaceutical

Tariff Impact Analysis: Key Insights for 2025

Global tariff negotiations across 180+ countries are reshaping supply chains, costs, and competitiveness. This report reflects the latest developments as of April 2025 and incorporates forward-looking insights into the market outlook.

The analysts continuously track trade developments worldwide, drawing insights from leading global economists and over 200 industry and policy institutions, including think tanks, trade organizations, and national economic advisory bodies. This intelligence is integrated into forecasting models to provide timely, data-driven analysis of emerging risks and opportunities.

What's Included in This Edition:

• Tariff-adjusted market forecasts by region and segment
• Analysis of cost and supply chain implications by sourcing and trade exposure
• Strategic insights into geographic shifts

Buyers receive a free July 2025 update with:

• Finalized tariff impacts and new trade agreement effects
• Updated projections reflecting global sourcing and cost shifts
• Expanded country-specific coverage across the industry